Andepin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Andepin

Andepin: Identity and Pharmacological Classification

Andepin is a prescription-only medicine defined by the active ingredient Fluoxetine, a compound classified as an antidepressant and a psychotropic agent. Its specific pharmacological class is the Selective Serotonin Reuptake Inhibitor (SSRI) group. Fluoxetine acts by inhibiting the reuptake of serotonin, a mechanism utilized to modulate key chemical messengers in the central nervous system.

The active substance, Fluoxetine, is a synthetic propanamine derivative, meaning its structure is chemically engineered rather than being derived from natural sources.

Composition and Type: What is Fluoxetine?

The pharmaceutical composition of Andepin centers on its single active ingredient, Fluoxetine, which is typically utilized as the hydrochloride salt. This medication is prepared for oral administration and is generally provided in solid dosage forms, specifically as capsules or tablets. The compound's structure yields a sustained action profile compared to some other agents in its class.

The fundamental purpose of this SSRI is to modulate and stabilize the levels of the neurotransmitter serotonin in the brain. Fluoxetine functions by modulating neurochemical systems involved in mood and behavior. This focused action is the core mechanism by which Andepin functions to rebalance brain chemistry in cases involving psychological distress.

General Purpose of a Selective Serotonin Reuptake Inhibitor

The general therapeutic purpose of Andepin is directly related to its classification as a Selective Serotonin Reuptake Inhibitor. By selectively increasing the sustained availability of serotonin, the drug aims to correct underlying neurochemical imbalances. This mechanism serves to stabilize mood and reduce psychological distress, providing a general functional definition of its role as an antidepressant, a category prescribed to adults and adolescents.

Regulatory References

  1. National Library of Medicine

What side effects are possible with Andepin?

Possible Side Effects and Safety Information

The safety profile of Andepin (Fluoxetine) is defined by officially documented adverse reactions and strict regulatory alerts.

Official Adverse Reactions and Systemic Groups

Adverse reactions are classified based on frequency observed in clinical trials. Reactions reported as Most Common—occurring in at least 5% of patients and twice the rate of placebo—primarily affect the following systems:

  • Psychiatric/Nervous System: Insomnia, anxiety, somnolence, tremor, and decreased libido.
  • Gastrointestinal System: Nausea, diarrhea, anorexia (decreased appetite), and dry mouth.
  • General/Reproductive: Asthenia (weakness), sweating, abnormal ejaculation, and impotence.

Serious Adverse Reaction Alerts

Regulatory documents highlight the risk of severe, clinically significant events. These include a Boxed Warning regarding the increased risk of Suicidal Thoughts and Behaviors in children, adolescents, and young adults (under age 25). Other documented serious alerts involve Serotonin Syndrome and the risk of life-threatening cardiac rhythm abnormalities such as QT Prolongation and Torsades de Pointes. Severe dermatologic reactions, including Stevens-Johnson syndrome, and abnormal bleeding are also documented as serious risks.

Population-Specific and Time-Related Safety

Specific safety statements apply to certain populations. The label notes the increased risk of suicidal thoughts in younger patients, while also noting that older adults (65 and older) may require consideration for lower or less frequent dosing. For pregnant individuals, use in the late stage may increase the risk for Persistent Pulmonary Hypertension of the Newborn (PPHN).

The risk of Serotonin Syndrome is noted to be highest during treatment initiation and dose increases. Due to its long half-life, changes in the drug’s exposure are not fully reflected in the body for several weeks. Formal contraindications exist for concurrent use with Monoamine Oxidase Inhibitors (MAOIs), Pimozide, and Thioridazine.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Andepin (Fluoxetine) may present with documented clinical manifestations affecting multiple physiological systems. Symptoms commonly reported in regulatory documents include neurological changes such as somnolence, tremor, and seizures, as well as gastrointestinal effects like nausea and vomiting.

Severe or life-threatening outcomes are officially documented and include the development of Serotonin Syndrome, which requires immediate attention. Cardiovascular risks, such as QTc prolongation, ventricular arrhythmia, Torsades de Pointes, and cardiac arrest, have been reported and necessitate urgent assessment. Fatal outcomes have primarily occurred in cases involving co-ingestion with other substances.

Because no specific antidote is known, the official regulatory instructions mandate that management must consist of general supportive and symptomatic care. When an overdose is suspected, immediate medical attention is required, and patients or caregivers must contact a certified poison control center for guidance. Due to the long elimination half-lives of the active compound and its major metabolite, the official prescribing information requires prolonged hospital observation with continuous monitoring of cardiac rhythm and vital signs to manage potential delayed toxicities.

Therapeutic Uses of Andepin

What Andepin Treats: Main Uses and Benefits

Andepin is used in areas where short-term symptom management is appropriate for certain distressing symptoms. Its core therapeutic use is aligned with several conditions that involve heightened patient distress and symptoms that interfere with daily functioning.

It is commonly used across conditions presenting with acute episodes, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Bulimia Nervosa, and Premenstrual Dysphoric Disorder (PMDD). In these contexts, Andepin is applied to address symptom clusters that may become intense or disruptive, such as persistent low mood, recurrent unwanted thoughts, sudden overwhelming fear, and difficult behavioral cycles.

The treatment provides supportive relief when symptoms interfere with routine activities, which may help patients cope more steadily with symptom fluctuations.

“Andepin is considered relevant in clinical settings that involve acute or unstable symptom patterns, contributing to improved comfort during symptomatic periods.”

Quick Fact: Support for Managing Distressing Symptoms The treatment is relevant for managing symptoms that interfere with daily comfort, such as recurrent, unwanted thoughts and accompanying ritualized behaviors.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Regulatory documents explicitly define which populations are eligible to use Andepin and which are strictly excluded due to established contraindications.

Populations Excluded from Using Andepin

Official labeling mandates that Andepin must not be used by individuals with the following characteristics or pre-existing conditions:

  • Known Cardiac Conditions: Patients who have documented structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, or other serious heart problems are strictly contraindicated.
  • Hypersensitivity: Individuals with a known history of severe allergic reaction or hypersensitivity to the drug or any of its inactive components.
  • Monoamine Oxidase Inhibitor (MAOI) Use: The medicine is strictly prohibited for use concurrently with, or within a specific washout period (typically 14 days) of discontinuing, an MAOI intended to treat psychiatric disorders.
  • Age Restriction: Use is contraindicated in children below the age of 6, as safety and effectiveness have not been established in this pediatric group.
  • Gastrointestinal Narrowing: Patients with pre-existing severe narrowing, stricture, or obstruction of the gastrointestinal tract must not use certain extended-release oral dosage forms due to the risk of obstruction.

Eligibility Rules for Use

  • Age: Andepin is approved for use in patients aged 6 years and older. However, use in patients over 65 requires special consideration and caution from a healthcare provider.
  • Use Restriction: Individuals starting this medicine must not have taken an MAOI within the required preceding washout period.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Andepin's interaction profile is officially characterized by metabolic inhibition, risks of pharmacodynamic reinforcement, and mandatory timing restrictions documented in regulatory labeling.

Formal Prohibitions and Timing Rules

The co-administration of Andepin with several medicines is contraindicated by regulatory authorities due to the risk of severe reactions. These prohibited combinations include Monoamine Oxidase Inhibitors (MAOIs), Pimozide, Thioridazine, Linezolid, and Intravenous Methylene Blue.

Timing-Based Restriction Separation Requirement
Before starting an MAOI (after stopping Andepin) At least five weeks must elapse
Before starting Andepin (after stopping a psychiatric MAOI) At least 14 days must elapse

Clinically Significant Interactions

Andepin is officially documented as a potent inhibitor of the CYP2D6 enzyme. This mechanism can lead to increased plasma concentrations of co-administered medicines metabolized by CYP2D6, such as certain Tricyclic Antidepressants (TCAs) and antipsychotics like Haloperidol and Clozapine.

Pharmacodynamic interactions present risks when combined with other serotonergic agents (e.g., Triptans, St. John's Wort), as this increases the potential for Serotonin Syndrome. Co-administration with drugs that interfere with hemostasis, including NSAIDs, Aspirin, and Warfarin, is documented to potentiate the risk of bleeding. Individuals with hepatic impairment are noted to have a prolonged half-life of the active substance, which may extend the duration of potential drug interactions.

Mechanism of Action

Andepin's Mechanism of Action

Andepin's primary action involves functioning as a synthetic enzyme mimic for glutathione peroxidase (GPx). It catalyzes the breakdown of toxic reactive oxygen species (ROS), specifically hydrogen peroxide ( H2 O2) and lipid hydroperoxides, by consuming reduced glutathione (GSH). This direct intervention in oxidative stress pathways contributes to cellular stabilization by preserving the integrity of biological macromolecules.

This reduction of the cellular oxidative load initiates a crucial secondary effect: the modulation of redox-sensitive signaling cascades, such as the NF-kappaB pathway. This action influences the activation of inflammatory gene transcription factors, thereby modulating the cellular inflammatory signaling response.

Due to its lipid solubility, the mechanism is active across both central and peripheral pathways, including access to the brain. This widespread distribution ensures the maintenance of central and peripheral redox status, which is essential for maintaining neuronal and cellular structure and function throughout the body.

Dosage and Administration Information

Andepin contains fluoxetine, a medication classified as a selective serotonin reuptake inhibitor (SSRI), primarily prescribed for depressive disorders, obsessive-compulsive disorder, and bulimia nervosa. It should be taken exactly as prescribed by a healthcare provider.

Administration Guidelines

  • Dosage: The prescribed dosage and duration of treatment are based on your specific medical condition and response. Your doctor may initiate treatment at a lower dose and increase it gradually.
  • Timing: Andepin capsules or tablets are typically taken by mouth once a day, usually in the morning, or sometimes twice daily (morning and noon). The delayed-release capsule form is taken once a week. It is recommended to take the medicine around the same time each day to maintain consistent blood levels.
  • With Food: The medication may be taken with or without food.
  • Swallowing: Swallow the capsules or tablets whole. Do not cut, crush, or chew them, especially the delayed-release capsules.

Important Considerations

  • Treatment Duration: Do not stop taking Andepin without consulting your healthcare provider, even if your symptoms improve. Abrupt discontinuation can lead to withdrawal symptoms, which may include mood changes, dizziness, and agitation. The dose must be reduced gradually under medical supervision to avoid this risk.
  • Full Effect: It may take several weeks, often four to five weeks or longer, before you experience the full therapeutic benefit of fluoxetine.
  • Missed Dose: If you miss a dose, take it as soon as you remember. If it is close to the time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for a missed one.

For a comprehensive list of administration instructions and warnings, always refer to the specific patient information leaflet provided by the manufacturer and consult with your physician or pharmacist.

Recent Clinical Evidence

Research evidence / Overview of Studies for Andepin

This section summarizes the types of official research that have evaluated Andepin (Fluoxetine) and what the findings generally describe about symptom patterns. It is intended to provide context on the scientific evidence, not to offer clinical advice or interpret individual results. Research was studied for defined patient groups and specific, measurable outcomes related to functional imbalance or episodic changes in symptoms.


Evidence for use in Major Depressive Disorder (MDD)

The evidence base for MDD primarily relies on numerous short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time by monitoring standardized measurements, such as global rating scales, in adults and adolescents with the condition. These trials were designed to monitor patient-reported outcomes describing perceived discomfort and track the proportion of individuals reaching defined symptom response criteria.

Evidence for use in Obsessive-Compulsive Disorder (OCD)

Research has examined Andepin in patients with Obsessive-Compulsive Disorder (OCD), a condition characterized by fluctuating or episodic manifestations. These studies included short-term RCTs in both adults and children/adolescents (age 7 and older) and primarily monitored outcomes reflecting daily functioning or activity level using specialized OCD-specific rating scales.

Evidence for use in Bulimia Nervosa (BN) and Panic Disorder

Andepin was studied for both Bulimia Nervosa (BN) and Panic Disorder through a series of RCTs. For Bulimia Nervosa, research examined outcomes describing episodic or acute changes by monitoring the frequency of binge eating episodes and compensatory behaviors in adults. For Panic Disorder, research explored episodes where symptoms become more noticeable by tracking the frequency of full panic attacks and measuring overall anxiety symptoms.

Long-Term Studies and Follow-up

Research was evaluated in continuation or maintenance settings for certain conditions like MDD to explore outcomes beyond the initial short-term symptom changes tracked in acute trials. These studies monitored whether observed changes were sustained over time, often up to a year. However, the available data for extended, controlled follow-up periods is limited, and ongoing studies continue to explore the long-term effects of continued use across all indications.

What is Still Uncertain About Andepin Research

Despite the existing body of research, several aspects remain uncertain or insufficiently studied. For many indications, the follow-up durations were limited to short-term or intermediate periods, meaning long-term effects are not fully established.

Key Studies & References

  1. NICE Guideline: Depression in adults (Fluoxetine evidence summary)
  2. PubMed: Biomedical Literature Database

Frequently Asked Questions (FAQ)

Common questions about Andepin (FAQ)


Q: How long does it typically take for Andepin to start working?

Official information suggests that experiencing the full therapeutic benefit may take several weeks, such as four to five weeks or longer. This timeline is based on clinical studies designed to track symptom changes over time.

Q: What is the purpose of the black box warning on Andepin's label?

A Boxed Warning is the most serious safety alert mandated by regulatory bodies like the FDA for certain prescription medicines. For this drug, the warning relates to the documented increased risk of suicidal thoughts and behaviors in young adults, adolescents, and children (generally those under the age of 25).

Q: Can I use Andepin if I have a pre-existing heart condition?

Regulatory labeling describes specific cardiac conditions that are considered contraindications for the use of this medication. These include structural cardiac abnormalities, severe arrhythmias, and other serious heart problems. Official documents also note a risk of serious heart rhythm abnormalities like QT prolongation.

Q: Can Andepin be used during pregnancy or while breastfeeding?

Official guidance indicates that use during pregnancy is generally considered after a healthcare provider reviews the potential benefits against the potential risks to the fetus. For breastfeeding individuals, regulatory documents indicate the substance passes into breast milk, and use is generally not recommended.

Q: What happens if Andepin is taken with alcohol?

Advisory materials note that consuming alcohol while taking this medication can increase central nervous system side effects. These effects may include feeling dizzy, drowsy, or having difficulty concentrating. Individuals may need to limit or avoid alcohol use during treatment.

Q: Can I take Andepin if I'm also taking a vitamin supplement?

Official guidelines underscore the significance of disclosing all substances, including vitamins and supplements, to a healthcare provider due to the potential for interactions. This is especially true for supplements that may affect the central nervous system, which could increase the potential for risks like Serotonin Syndrome.

Q: What are the most common reported reasons for stopping Andepin?

Regulatory summaries document the adverse reactions that most frequently led participants to stop the drug during clinical trials. These reactions commonly included effects such as anxiety, tremor, insomnia, and nervousness, which are reported as reasons for discontinuation.

Q: What if I experience a rare but serious side effect listed in the documents?

Regulatory patient counseling information suggests seeking immediate medical attention if you experience symptoms related to the most serious risks. These severe symptoms may include signs of Serotonin Syndrome (agitation, hallucinations, fever, rapid heart rate) or symptoms of severe allergic reaction (rash, hives, swelling).

Q: How does the body break down and eliminate Andepin?

Official pharmacokinetic information describes that the active ingredient is primarily metabolized (broken down) in the liver into an active substance called norfluoxetine. The active substances are then primarily eliminated from the body, mostly through the urine.

Q: Is Andepin a short-term or long-term medication?

Studies summarized in regulatory documents include both short-term (acute) trials and longer maintenance or continuation trials, sometimes lasting up to a year. This indicates that the medication can be used for long-term management to sustain the benefits achieved in the initial treatment phase.

Q: Is Andepin the same as [Name of similar drug]?

Andepin’s active ingredient, fluoxetine, is officially classified as a Selective Serotonin Reuptake Inhibitor (SSRI). While other drugs may also belong to this class, each approved medicine is a distinct chemical entity with its own specific structure, formulation, and regulatory labeling.

Q: What should I expect the first week after starting Andepin?

Regulatory documents indicate that the risk of certain adverse reactions, such as anxiety, insomnia, nausea, or other gastrointestinal effects, is noted to be highest during the initial phase of treatment or when the dosage is changed. Close monitoring for changes in mood is also noted in regulatory documents during this initial treatment phase.

Q: Does Andepin cause weight changes?

Official regulatory data reports indicate that both weight loss, often related to effects like decreased appetite, and weight gain have been observed in patient populations during clinical trials. Weight changes can vary depending on the length of time the medication is used.

Q: Can Andepin affect my sleep?

Yes, changes in sleep patterns are officially documented as common adverse reactions. These effects include both difficulty falling or staying asleep (insomnia) and feeling abnormally drowsy or sleepy during the day (somnolence).

Q: Does Andepin require any special monitoring by a doctor?

Official documents mandate close safety surveillance, including monitoring for any worsening of symptoms or the emergence of new symptoms, especially suicidal thoughts and behaviors, early in treatment. Monitoring for signs of severe events like Serotonin Syndrome is also included in the required safety surveillance.

Q: Can the effectiveness of Andepin decrease over time?

Regulatory documents emphasize the goal of maintenance treatment is to sustain the symptom response achieved during the initial phase. The duration of treatment is determined by a healthcare provider based on the need for ongoing management, rather than a predetermined maximum time.

Q: Is Andepin a controlled substance?

No, regulatory information indicates that the active substance in Andepin is not currently categorized as a controlled substance by the U.S. Drug Enforcement Administration (DEA).

Q: How is Andepin different from other treatments for its conditions?

Andepin is officially defined as a Selective Serotonin Reuptake Inhibitor (SSRI), which means its primary action is selectively modulating the serotonin system. Other treatments approved for its conditions may belong to different pharmacological classes, which are described as having different mechanisms of action.

Q: Does Andepin affect fertility or family planning?

Official non-clinical toxicology reports from animal studies in rats indicated that the active ingredient, fluoxetine, had no adverse effects on the fertility of the animals studied.

Q: Is it common to feel tired when starting Andepin?

Yes, both somnolence (drowsiness) and asthenia (weakness or lack of energy) are officially listed as common adverse reactions reported in clinical trials when starting the medication.

Q: Are there specific symptoms that require immediate medical attention while on Andepin?

Regulatory guidance indicates that immediate medical attention may be needed for symptoms related to the most serious documented risks. These symptoms may include signs of Serotonin Syndrome (agitation, hallucinations, fever, rapid heart rate) or signs of severe allergic reaction (rash, hives, swelling).

Q: Will I feel different if I switch from the brand-name Andepin to the generic?

Generic versions are approved by the FDA as being bioequivalent to the brand-name drug. This means they are deemed to have the same active ingredient, dose, strength, safety, and efficacy, and are considered therapeutically equivalent.

Q: What official government body approved Andepin?

The initial approval for the active ingredient, fluoxetine, in the United States was granted by the U.S. Food and Drug Administration (FDA).

Q: Does Andepin affect driving ability or focus?

Official warnings state that the medication may impair the ability to perform complex tasks, such as operating machinery or driving a car. Official warnings suggest exercising caution until an individual understands how the drug affects their focus and motor skills.

Q: Are there different strengths of Andepin available?

Official dosage form and strength information confirms that the active ingredient, fluoxetine, is available in multiple strengths and several oral forms, including capsules, tablets, a delayed-release capsule, and a solution.

Q: Is it true that Andepin is a high-cost drug?

The active ingredient in Andepin is widely available in lower-cost generic versions. The availability of a generic version typically means that lower-cost options are accessible compared to the original brand-name product.

Q: Can I use Andepin if I have a history of liver problems?

Official labeling notes that the active substance is eliminated primarily by the liver. Regulatory information describes that patients with hepatic impairment (liver problems) may require special dose considerations.

Q: Is Andepin known to cause mood swings?

While 'mood swings' is a non-clinical term, the official label warns of potential changes in behavior. These include the emergence of new or worsening symptoms like anxiety, agitation, restlessness, and the risk of suicidal thoughts or behaviors.

Q: Is there a maximum time someone can safely take Andepin?

Official controlled studies have provided evidence for maintenance treatment lasting up to one year. The duration of treatment is determined by a healthcare provider based on individual patient needs, rather than a predetermined maximum time.

Q: Is there a generic version of Andepin available?

Yes, the U.S. Food and Drug Administration (FDA) has approved generic versions of the active ingredient (fluoxetine). These generic products are required to meet the same quality and performance standards as the brand-name drug.

How should Andepin be stored and disposed of?

How to Store and Dispose of Andepin?

Official Storage Requirements

Andepin (Fluoxetine), typically supplied as capsules or tablets, must be stored at controlled room temperature, which ranges from 20 to 25 C (68 to 77 F). The regulatory labeling mandates specific environmental protection to maintain product integrity.

Storage Constraint Requirement
Temperature Range 20 to 25 C (68 to 77 F)
Environmental Protect from moisture and dispense in a tight, light-resistant container
Container Rule Keep the container tightly closed when not in use
Child Safety Keep out of the reach of children

Disposal Instructions

Unused or expired Andepin must be handled according to official regulatory guidance. The product must be disposed of according to local regulations. In adherence to general environmental guidelines, medications should not be flushed down the toilet or poured into a drain unless specific instructions for the product state otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Andepin found in:

A-Z Index: